European Journal of Therapeutics is a distinguished journal dedicated to advancing the field of therapeutic sciences through high-quality research and innovative clinical practice. Published by Pera Yayincilik Hizmetleri, this interdisciplinary journal aims to facilitate knowledge dissemination in areas such as pharmacology, clinical medicine, and public health, thereby supporting both researchers and practitioners in improving therapeutic outcomes. Although the journal operates under a subscription model, its commitment to rigorous peer review ensures that published articles reflect the latest advancements and methodologies. With a growing emphasis on evidence-based therapies, the European Journal of Therapeutics serves as a vital platform for dialogue among healthcare professionals and researchers, enhancing the understanding of therapeutic interventions on a global scale. It welcomes contributions ranging from original research to review articles, making it an essential resource for those seeking to enrich their knowledge and influence practice in therapeutic approaches.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

Mayo Clinic Proceedings is a premier peer-reviewed medical journal published by Elsevier Science Inc, dedicated to advancing clinical practice through high-quality research, reviews, and case reports since its inception in 1945. With an impressive impact factor and recognized as a Q1 journal in the Medicine (miscellaneous) category, it ranks as #21 out of 636 in the realm of General Medicine, placing it in the top 96th percentile among its peers. The journal serves as a vital resource for healthcare professionals, researchers, and students by promoting evidence-based medicine that addresses contemporary challenges in clinical practice. Although it does not currently offer open access options, its rigorous publication standards ensure that its findings are credible and relevant, making it an essential platform for disseminating significant medical advancements. With a commitment to progress in healthcare, the Mayo Clinic Proceedings continues to shape the future of medicine for audiences across the globe.

HEALTH TECHNOLOGY ASSESSMENT is a prestigious open-access journal published by the NIHR Journals Library, focusing on advancing the science of health technology assessment through robust research and critical analysis in the fields of Health Policy and Medicine. Since its inception in 2001, this journal has fostered a multidisciplinary approach to evaluating health technologies, offering invaluable insights to researchers, healthcare professionals, and policymakers. With an impressive Q1 ranking in both Health Policy and Medicine (miscellaneous) for 2023, it stands at the forefront of academic discourse, reflecting a high-impact factor and an esteemed reputation within its respective categories. The journal not only publishes original research articles, but also reviews and case studies that illuminate the complexities of health technology in real-world applications. Established and based in the United Kingdom, HEALTH TECHNOLOGY ASSESSMENT strives to encourage evidence-based decision-making, making it an essential resource for anyone committed to enhancing healthcare outcomes through innovative technology assessments.

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION (JPMA), published by the Pakistan Medical Association, serves as a vital platform for the dissemination of peer-reviewed research in the field of general medicine. Established in 1966, this journal has grown to cater to a diverse audience of healthcare professionals, researchers, and students, delivering crucial insights into the evolving landscape of medical science in Pakistan and beyond. With an ISSN of 0030-9982, JPMA aims to bridge knowledge gaps by publishing high-quality original articles, reviews, and case studies, fostering academic excellence and enhancing clinical practice. While the journal currently holds a Q4 category in Medicine (miscellaneous), it ranks #331 out of 636 in the Scopus database, placing it within the 48th percentile among its peers. The journal's critical role in shaping medical discourse ensures it remains an essential resource for advancing healthcare standards and improving patient outcomes.

The Journal of the National Comprehensive Cancer Network (ISSN: 1540-1405, E-ISSN: 1540-1413) is a premier publication in the field of oncology, established by HARBORSIDE PRESS and running since 2003. This highly respected journal holds a remarkable Q1 ranking in both Medicine (Miscellaneous) and Oncology categories, showcasing its significant influence and contribution to cancer research, with a Scopus ranking placing it within the top 5% of its field (Rank #20 out of 404). Aimed at a diverse audience including researchers, clinicians, and students, the journal publishes a wide range of articles that explore cutting-edge findings, clinical practices, and evidence-based guidelines in cancer care. With its commitment to advancing the understanding and treatment of cancer, it serves as a vital resource for professionals dedicated to improving patient outcomes. Although it does not currently offer open access, its impactful content continues to be a cornerstone for anyone involved in oncology research and practice.

JAMA Internal Medicine is a premier scholarly journal published by the American Medical Association, renowned for its rigorous peer-review process and commitment to advancing the field of internal medicine. With an impressive impact factor that positions it in the upper echelon of medical journals, specifically ranked at Q1 in Internal Medicine and holding a remarkable Scopus rank of #2 out of 167, the journal provides a vital platform for original research, reviews, and enlightening discussions that shape clinical practices and policies. As an accessible repository of cutting-edge findings and comprehensive analyses, JAMA Internal Medicine offers both subscription and open access options, ensuring that the latest developments in medicine are available to clinicians, researchers, and the academic community at large. With its focus spanning from 2013 to 2024 and its dedication to high-quality scholarship, the journal serves as an essential resource for those seeking to enhance their understanding of the complexities of internal medicine and improve patient care.

EXPERT OPINION ON BIOLOGICAL THERAPY, published by Taylor & Francis Ltd, is a prestigious journal that has been a cornerstone in the fields of Clinical Biochemistry, Drug Discovery, and Pharmacology since its inception in 2001. With an impressive impact factor reflecting Q1 status across its categories in 2023, this journal is ranked among the top in both the pharmacology and biochemistry domains, featuring in the 81st and 77th percentiles respectively. This makes it an essential resource for researchers, professionals, and students who are keen on staying at the forefront of biological therapy advancements. The journal encompasses a broad yet focused scope, providing valuable insights into innovative therapeutic strategies and drug development methodologies. Researchers benefit from the rigorous peer-review process and the opportunity to disseminate their findings to a global audience, without the constraints of open access, ensuring the integrity and prestige of published work. As it converges towards 2024, EXPERT OPINION ON BIOLOGICAL THERAPY remains an influential platform for fostering collaboration and discussion in the evolutionary landscape of biological therapies.

EXPERT OPINION ON EMERGING DRUGS, published by Taylor & Francis Ltd, stands at the forefront of the pharmacological sciences, focusing on the rapid development and evaluation of innovative therapeutic agents. With an impressive impact factor that reflects its contributions to the field, this journal is indexed under ISSN 1472-8214 and E-ISSN 1744-7623. The journal has consistently attained high recognition, currently holding a Q2 ranking in Pharmacology and a Q1 ranking in Pharmacology (medical) as of 2023, which places it within the top tiers of scholarly publications. Covering a broad range of topics related to emerging pharmaceuticals, it aims to bridge the gap between research and clinical practice by providing critical reviews, expert opinions, and insightful analyses. Based in the United Kingdom and actively published since 2000, the journal seeks to inform and inspire researchers, professionals, and students alike, offering a platform to foster collaboration and insight within the ever-evolving domain of drug development and pharmacotherapy.